Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
about
Antigen-specific active immunotherapy for ovarian cancerAntigen-specific active immunotherapy for ovarian cancerAndrogen receptor molecular biology and potential targets in prostate cancerTreatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1Endogenous Antigen Presentation of MHC Class II Epitopes through Non-Autophagic PathwaysImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerMAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerTumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes.Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.Identification of a dual-specific T cell epitope of the hemagglutinin antigen of an h5 avian influenza virus in chickens.Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosisGenome-wide analysis of cancer/testis gene expression.Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.Ovarian cancer immunotherapy: opportunities, progresses and challengesIntertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancerTumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancerBORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.Characterization of intrinsically disordered prostate associated gene (PAGE5) at single residue resolution by NMR spectroscopyExpression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancerPotential target antigens for a universal vaccine in epithelial ovarian cancer.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development.Immunotherapy for ovarian cancer: what's next?Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stageGeneration and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.Configuration and rearrangement of the human GAGE gene clusters.A Panel of Cancer Testis Antigens and Clinical Risk Factors to Predict Metastasis in Colorectal Cancer.Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
P2860
Q24193567-45F3FDF3-6794-4220-9D25-C26918DB1CA0Q24240962-440F5355-6A6A-4749-BFD6-754ED31E5941Q24602861-E84FE937-E172-40AF-A411-B85662B08A6BQ24633445-37655547-E8A7-44C8-98D5-88548C7095AEQ26781304-184E47E0-655B-4504-A02D-ABC5047069AAQ26996829-33E1B350-B413-4D9F-8D5B-DFAAA4061FC5Q28478930-23418DFD-B352-431E-9581-215B058193C9Q29616128-B9AE0152-5EBF-45D5-B6D1-301EE2E20DB1Q30558949-066779ED-5DA3-45A7-AB1E-0808BF506C01Q30667174-4B73072C-6903-4DB8-B306-1A83168D218DQ30879279-7C52318D-C070-4478-9520-8FABE79559B5Q31047715-37A94A6F-7338-44D0-B028-58920B405ED8Q33391074-F7711BA8-11AE-4633-8C58-B80F633BCF17Q33393581-1AFD79AE-5D52-4828-85AA-1BA397F82213Q33526746-83C9DDFD-8226-46F6-AE25-84B38643A833Q33691683-12C0DAF2-3D08-4C2F-8418-032774418594Q33702218-0A822082-B834-4B1D-BDE6-54AE4707790FQ33715446-102265FD-3359-4C46-8CC4-D38CEE5436FFQ33842859-DA81409D-17C7-4414-BF42-AE2A518084B4Q33857800-3D5A20BB-4DFF-43C1-B067-EA4F752802D0Q33999909-CD967A72-1090-492D-A92A-C2C6A09C42CBQ34015590-32AD2517-C079-4300-A401-CC0BC8C2535CQ34044914-35C23738-82F4-4756-ADE5-89DB97145B54Q34071587-90BA15E1-BDF5-4C32-A119-3CF0D2D2DC5FQ34111817-592F3E4E-33BA-4301-816C-24CBF5B56FD2Q34159451-F88A18A6-36CE-431E-9229-584E13B6202AQ34325790-96F7FACE-36C8-4535-8B20-0013C5D7B07EQ34402325-B73F951E-BDC2-4159-818B-15744115BDD9Q34476278-FDA782D9-FC8B-4A52-A12B-9F4CBCD158CAQ34669311-B2898528-1590-4F37-8614-3A203C6E4413Q34743514-B47FEBC1-D825-4A3B-8EE6-E3BF0204B27FQ34795079-DBCFAC42-EE1E-4467-8319-C393CE0DC502Q34810674-47DB002E-572C-4F4B-BAB2-A2609640E9CDQ34843832-0F8B0B87-C5FE-43C2-B0C9-7FC232A8CFD4Q35008960-DA543F12-1005-4F13-83FD-A5F59AD88F03Q35623585-EA593964-536C-4012-818E-3F6DEDD1F50BQ35889432-E83BD76E-5CB0-4B96-9A17-FC7253116A6BQ35996647-78D0565A-A56E-46CE-924E-D0DBB6DB4D1FQ36075245-F39C8BEA-6335-49DB-89EE-C983E6F53998Q36214731-198EEA34-E54E-46EB-B67D-DF8FC2D9C26A
P2860
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vaccination with an NY-ESO-1 p ...... l responses in ovarian cancer.
@ast
Vaccination with an NY-ESO-1 p ...... l responses in ovarian cancer.
@en
type
label
Vaccination with an NY-ESO-1 p ...... l responses in ovarian cancer.
@ast
Vaccination with an NY-ESO-1 p ...... l responses in ovarian cancer.
@en
prefLabel
Vaccination with an NY-ESO-1 p ...... l responses in ovarian cancer.
@ast
Vaccination with an NY-ESO-1 p ...... l responses in ovarian cancer.
@en
P2093
P2860
P356
P1476
Vaccination with an NY-ESO-1 p ...... l responses in ovarian cancer.
@en
P2093
Bridget Thomas
Christopher Andrews
Eric W Hoffman
Gerd Ritter
Jeannine Villella
Junko Matsuzaki
Kerry Rodabaugh
Lloyd J Old
P2860
P304
12837-12842
P356
10.1073/PNAS.0703342104
P407
P50
P577
2007-07-25T00:00:00Z